NVS · NYSE, OTC · CIK 0001114448

NOVARTIS AG

NOVARTIS AG’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
$14.0B
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
NOVARTIS AG
Tickers
NVS, NVSEF
SEC Central Index Key (CIK)
0001114448
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
BASEL, Switzerland
State or country of incorporation
Switzerland
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#39 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from NOVARTIS AG’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
$24.0BFY2021$7.0BFY2022$14.9BFY2023$11.9BFY2024$14.0BFY2025
NVS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income$24.0B$7.0B$14.9B$11.9B$14.0B
Diluted EPS$10.63$3.17$7.10$5.87$7.15
Total assets$131.8B$117.5B$99.9B$102.2B$110.9B
Cash and equivalents$3.4B$2.9B$3.2B$2.6B$2.6B

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

NVS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 4, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 27, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about NOVARTIS AG, by form type:

6-K ×15DFAN14A ×6424B5 ×4S-8 POS ×4144 ×3FWP ×23 ×1SCHEDULE 13G/A ×1IRANNOTICE ×120-F ×1S-8 ×1SC TO-T/A ×1
NVS recent filings
FiledFormWhat it isOriginal
Oct 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 27, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 4, 20266-KReport of a foreign private issuer· period Sep 4, 2026Document · Index
Sep 1, 20266-KReport of a foreign private issuer· period Sep 1, 2026Document · Index
Jul 21, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jun 11, 20266-KReport of a foreign private issuer· period Jun 11, 2026Document · Index
Apr 30, 2026144Notice of proposed sale of securitiesDocument · Index
Apr 28, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Mar 18, 20266-KReport of a foreign private issuer· period Mar 18, 2026Document · Index
Mar 17, 2026424B5424B5Document · Index
Mar 17, 2026FWPFWPDocument · Index
Mar 16, 2026424B5424B5Document · Index
Feb 12, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 9, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 4, 20266-KReport of a foreign private issuer· period Dec 31, 2025Document · Index
Feb 4, 20266-KReport of a foreign private issuer· period Dec 31, 2025Document · Index
Feb 4, 2026IRANNOTICEIRANNOTICEDocument · Index
Feb 4, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Feb 4, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jan 16, 2026S-8 POSS-8 POSDocument · Index
Jan 16, 2026S-8 POSS-8 POSDocument · Index
Jan 16, 2026S-8 POSS-8 POSDocument · Index
Jan 16, 2026S-8 POSS-8 POSDocument · Index
Jan 14, 2026DFAN14ADFAN14ADocument · Index
Jan 12, 2026DFAN14ADFAN14ADocument · Index
Nov 25, 20256-KReport of a foreign private issuer· period Nov 24, 2025Document · Index
Nov 20, 20256-KReport of a foreign private issuer· period Nov 20, 2025Document · Index
Nov 5, 20256-KReport of a foreign private issuer· period Nov 5, 2025Document · Index
Nov 4, 2025424B5424B5Document · Index
Nov 4, 2025FWPFWPDocument · Index
Nov 3, 2025424B5424B5Document · Index
Oct 28, 20256-KReport of a foreign private issuer· period Sep 30, 2025Document · Index
Oct 28, 2025DFAN14ADFAN14ADocument · Index
Oct 28, 20253Initial statement of beneficial ownership· period Oct 28, 2025Document · Index
Oct 28, 2025SC TO-T/ASC TO-T/ADocument · Index
Oct 28, 2025DFAN14ADFAN14ADocument · Index
Oct 27, 20256-KReport of a foreign private issuer· period Oct 27, 2025Document · Index
Oct 27, 2025DFAN14ADFAN14ADocument · Index
Oct 27, 2025DFAN14ADFAN14ADocument · Index

Insider filing activity

0 Form 4 filings appear in NOVARTIS AG’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001114448 and XBRL company facts. NOVARTIS AG on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.